Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Akero Therapeutics, Inc
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and non-pregnant, non-lactating females between 18-75 years of age inclusive, based on the date of signing informed consent.
Main Study Only: Previous history or presence of Type 2 diabetes or 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose).
Main Study Only: Biopsy-proven compensated cirrhosis due to NASH.
Cohort D Only: Diagnosis of type 2 diabetes
Cohort D Only: Use of GLP-1R agonist for at least 90 days
Cohort D Only: Biopsy-proven liver fibrosis stages 1, 2, or 3
You may not be if
Main Study Only: Weight loss \> 10% in the 90 days prior to screening until randomization or from the time of collection of the liver biopsy used to assess subject eligibility until randomization, whichever is longer.
Type 1 diabetes or uncontrolled Type 2 diabetes
Cohort D Only: Weight loss \> 5% in the 90 days prior to screening
Cohort D Only: Presence of cirrhosis on liver biopsy
Clareo Health | A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
